地高辛致不良反应相关因素分析及防治

doi:10.19803/j.1672-8629.20230297

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (11): 1269-1272.
DOI: 10.19803/j.1672-8629.20230297

地高辛致不良反应相关因素分析及防治

王丽, 于文雯, 李敏, 郭瑞惠, 曹广生, 戚迎梅^*

济南市药品不良反应和医疗器械不良事件监测中心,山东济南 250013

收稿日期:2023-05-12 出版日期:2023-11-15 发布日期:2023-11-13
通讯作者: ^*戚迎梅,女,硕士,副主任药师,药物警戒。E-mail: 781164184@qq.com
作者简介:王丽,女,硕士,主管药师,药物警戒。

Risk factors and precautions for adverse drug reactions caused by Digoxin

WANG Li, YU Wenwen, LI Min, GUO Ruihui, CAO Guangsheng, QI Yingmei^*

Jinan Adverse Drug Reaction and Medical Device Adverse Event Monitoring Center, Jinan Shandong 250013, China

Received:2023-05-12 Online:2023-11-15 Published:2023-11-13

摘要/Abstract

摘要： 目的介绍地高辛所致药品不良反应（adverse drug reaction,ADR）相关风险因素及防治措施,以减少药品不良反应发生,保证临床安全合理用药。方法通过查阅相关文献,就地高辛所致ADR临床症状、ADR相关风险因素、防治措施、地高辛中毒监测与解救等方面进行系统综述。结果地高辛所致ADR临床症状与原患疾病症状相似,相关风险因素错综复杂,包括年龄、性别、药物相互作用、肝肾状态、采血时间、遗传因素、给药剂量、用药依从性等多方面,往往中毒反应一旦发生就较为严重。结论临床用药过程中应尽可能避免引起ADR的相关因素,并为患者提供科学的用药指导,尽量减少中毒反应和ADR发生,以保证地高辛的临床用药安全。

关键词: 地高辛, 药品不良反应, 强心苷类, 防治, 心力衰竭, 风险因素, 中毒

Abstract: Objective To study the risk factors and precautions for adverse drug reactions(ADR) caused by digoxin so as to ensure safe and rational use of this drug. Methods Based on related literature, digoxin-related ADR, risk factors, precautions, digoxin poisoning monitoring and treatments were reviewed. Results ADR caused by digoxin were similar to the first symptoms of the disease. Age, gender, drug interactions, liver and kidney function, timing of blood collection, genetic factors, dosage, administration compliance, and other variables were among the wide range of risk factors for ADR. Toxic reactions were severe once they occurred. Conclusion The risk factors should be avoided to the great extent possible during administration. Patients should be given proper administrations in order to minimize intoxication reactions and other ADR.

Key words: digoxin, adverse drug reaction, cardiac glycosides, precaution, heart failure, risk factors, intoxication

中图分类号:

R994.11
R972

王丽, 于文雯, 李敏, 郭瑞惠, 曹广生, 戚迎梅. 地高辛致不良反应相关因素分析及防治[J]. 中国药物警戒, 2023, 20(11): 1269-1272.

WANG Li, YU Wenwen, LI Min, GUO Ruihui, CAO Guangsheng, QI Yingmei. Risk factors and precautions for adverse drug reactions caused by Digoxin[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1269-1272.

参考文献

[1] BOTELHO AFM, PIEREZAN F, SOTO-BLANCO B, et al.A review of cardiac glycosides: structure, toxicokinetics, clinical signs, diagnosis and antineoplastic potential[J]. Toxicon, 2019, 158: 63-68.
[2] SUN XY, HE M, WEI MJ.Research progress of digoxin as an anti-tumor candidate drug[J]. Chin J New Drugs Clin Rem(中国新药与临床杂志), 2021, 40(8): 545-549.
[3] MA BS, YANG K.Analysis of serum digoxin concentration monitoring results and influencing factors in 127 cases[J]. Central South Pharmacy(中南药学), 2023, 21(8): 2195-2200.
[4] WANG H.Blood digoxin concentration monitoring and its influencing factors[J]. Chin J of Clinical Rational Drug Use, 2022,15(4): 158-160.
[5] SHI H.Analysis on influence of clinical pharmacist intervention on blood drug concentration monitoring of digoxin and individualized medication[J]. Chinese Community Doctors(中国社区医师), 2023, 39(1): 15-17.
[6] ZHOU HY, CHEN RT, FANG XC, et al.Clinical retrospective analysis of 122 cases of digoxin poisoning[J]. Heilongjiang Medicine Journal(黑龙江医药), 2018, 31(2): 286-289.
[7] TAN JQ, HUANG YL, HU YZ.Monitoring and analysis of digoxin blood concentration in 2064 inpatients[J]. Guangdong Medical Journal(广东医学), 2019, 40(18): 2610-2614.
[8] KENAWY AS.The impact of electronic prescription on reducing medication errors in an egyptian outpatient clinic[J]. International Journal of Medical Informatics, 2019, 127(7): 80-87.
[9] GAO L, XIAO JQ, HE GP.Clinical characteristics and related factors of digoxin intoxication in 78 cases[J]. China Pharmaceuticals(中国药业), 2017, 26(10): 66-68.
[10] LI Q, PAN GX.A review of the pharmacokinetic interaction of digoxin[J]. Liaoning Journal of Traditional Chinese Medicine(辽宁中医杂志), 2011, 38(4): 704-705.
[11] SUN WW.Analysis of concentration monitoring results of digoxin in 404 patients[J]. Chin Hosp Pharm(中国医院药学杂志), 2013, 33(20): 1732-1734.
[12] REN JW.New use of old drugs cardiac glycosides[J]. Chin J Cardiovase Rehabil Med(心血管康复医学杂志), 2022, 31(2): 210-213.
[13] XU L, YANG Y, YIN DK.Research progress in oral absorption and pharmacokinetics of digoxin[J]. China Pharmacist(中国药师), 2020, 23(11): 2248-2252.
[14] LI Y, LIU X.Drug interactions of digoxin and its rational use[J]. Pharm Care & Res(药学服务与研究), 2008, 8(6): 461-464.
[15] YE XC, HUANG HG, ZHANG G.Effect of Qiliqiangxin Capsule on blood digoxin concentration[J]. Herald of Medicine(医药导报), 2019, 38(7): 955-957.
[16] CHENG SL, MIAO M, LIU J.Analysis on influencing factors of digoxin poisoning[J]. China J of Clinical Rational Drug Use(临床合理用药杂志), 2018, 11(19): 123-125.
[17] TANG C, TANG YQ.Comments by Beer criteria on proton pump inhibitors and digoxin prescriptions for elderly outpatients[J]. Chin J of Clinical Rational Drug Use(临床合理用药杂志), 2021, 14(2): 141-143.
[18] DAI Y.Clinical pharmacists participate in the treatment of digoxin overdose poisoning case analysis[J]. J Mod Med Health(现代医药卫生), 2020, 36(2): 307-310.
[19] General Office of the National Health Commission. On the issuance of long-term prescription management standards (trial) notice[EB/OL]. (2021-08-10)[2023-05-10]. https://www.gov.cn/zhengce/zhengceku/2021-08/13/content_5631140.htm.
[20] MA LP, YANG F, CAI JR.Analysis of digoxin dose of elderly outpatient prescriptions based on 2015 Beers Criteria[J]. Chinese Journal of Pharmacovigilence(中国药物警戒), 2016, 13(9): 563-566.
[21] LIN AL,WANG XQ, LI P.Observation and nursing for digoxin poisoning[J]. China Prac Med(中国实用医药), 2019, 14(11): 189-191.
[22] YAN L, WANG YY, YE LS.1 case of acute high dose digoxin poisoning[J]. J Mod Med Health(现代医药卫生), 2018, 34(4): 635-637.
[23] YAO XF.Analysis of 11 cases of digitalis poisoning[J]. China Academic Journal Electronic Publishing House(心电与循环), 2021, 40(2): 199-200.

地高辛致不良反应相关因素分析及防治

Risk factors and precautions for adverse drug reactions caused by Digoxin

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.